VALORIE MIXON: Open Payments
NPI 1285728006 · CHATSWORTH, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$588 in 30 payments from 15 companies in 2025. Trend: 2023 $374 · 2024 $408 · 2025 $588
Food & beverage: $588
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 6 | $116 |
| Novo Nordisk Inc | 4 | $88 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Medtronic, Inc. | 2 | $41 |
| Amgen Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
Products named: GEMTESA, Auvelity, CAPLYTA, TRELEGY ELLIPTA, GVOKE HYPOPEN, Ozempic, MOUNJARO, Rybelsus.
Industry payments across GA — which companies pay providers there.
